Modification of decoy oligodeoxynucleotides to achieve the stability and therapeutic efficacy

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1603-1607

  Osako, Mariana Kiomy ^a   Nakagami, Hironori ^a   Morishita, Ryuichi ^b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Decoy oligodeoxynucleotides nuclear factor B

Indexed keywords

DECOY OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN DECOY OLIGODEOXYNUCLEOTIDE; INTERCELLULAR ADHESION MOLECULE 1; NATURAL TYPE OLIGODEOXYNUCLEOTIDE; NUCLEASE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE; POLYGLACTIN; POLYMER; PROTHROMBIN; RIBBON TYPE OLIGODEOXYNUCLEOTIDE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOPLASTY; BINDING AFFINITY; BIODEGRADABILITY; CELL DIFFERENTIATION; CHEMICAL MODIFICATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; HYPERPLASIA; IN VIVO STUDY; LOW DRUG DOSE; NEOINTIMA; OSTEOCLASTOGENESIS; PHOSPHOROTHIOATION; PROMOTER REGION; PROTEINURIA; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; BASE SEQUENCE; BINDING SITES; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG STABILITY; HUMANS; LACTIC ACID; MOLECULAR SEQUENCE DATA; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; POLYGLYCOLIC ACID; TRANSCRIPTION, GENETIC;

EID: 84867511104     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531397     Document Type: Review

References (30)

1. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131(5), 861-872.
2. Morishita, R.; Sugimoto, T.; Aoki, M.; Kida, I.; Tomita, N.; Moriguchi, A.; Maeda, K.; Sawa, Y.; Kaneda, Y.; Higaki, J.; Ogihara, T., In vivo transfection of cis element decoy against nuclear factor-kappaB binding site prevents myocardial infarction. Nat. Med., 1997, 3(8), 894-899.
3. Miyake, T.; Aoki, M.; Nakashima, H.; Kawasaki, T.; Oishi, M.; Kataoka, K.; Tanemoto, K.; Ogihara, T.; Kaneda, Y.; Morishita, R., Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFkappaB and ets using chimeric decoy oligonucleotides in a rabbit model. Gene. Ther., 2006, 13(8), 695-704.
4. Yamasaki, K.; Asai, T.; Shimizu, M.; Aoki, M.; Hashiya, N.; Sakonjo, H.; Makino, H.; Kaneda, Y.; Ogihara, T.; Morishita, R., Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene. Ther., 2003, 10(4), 356-64.
5. Yoshimura, S.; Morishita, R.; Hayashi, K.; Yamamoto, K.; Nakagami, H.; Kaneda, Y.; Sakai, N.; Ogihara, T., Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene. Ther., 2001, 8(21), 1635-1642.
6. Jun-Ichi, S.; Hiroshi, I.; Ryo, G.; Ryuichi, M.; Kensuke, E.; Mitsuaki, I., Initial clinical cases of the use of a NF-kappaB decoy at the site of coronary stenting for the prevention of restenosis. Circ. J., 2004, 68(3), 270-271.
7. Egashira, K.; Suzuki, J.; Ito, H.; Aoki, M.; Isobe, M.; Morishita, R., Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J. Gene. Med., 2008, 10(7), 805-809.
8. Suzuki, J.; Tezuka, D.; Morishita, R.; Isobe, M., An initial case of suppressed restenosis with nuclear factor-kappa B decoy transfection after percutaneous coronary intervention. J. Gene. Med., 2009, 11(1), 89-91.
9. Shimizu, H.; Nakagami, H.; Morita, S.; Tsukamoto, I.; Osako, M. K.; Nakagami, F.; Shimosato, T.; Minobe, N.; Morishita, R., New Treatment of Periodontal Diseases Using NFkB Decoy Oligodeoxunuclotides via Prevention of Bone Resorption and Promotion of Wound Healing. Antioxid Redox Signal, 2009.
10. Shimizu, H.; Nakagami, H.; Tsukamoto, I.; Morita, S.; Kunugiza, Y.; Tomita, T.; Yoshikawa, H.; Kaneda, Y.; Ogihara, T.; Morishita, R., NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene. Ther., 2006, 13(12), 933-941.
11. Morishita, R.; Gibbons, G. H.; Horiuchi, M.; Ellison, K. E.; Nakama, M.; Zhang, L.; Kaneda, Y.; Ogihara, T.; Dzau, V. J., A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA, 1995, 92(13), 5855-9.
12. Kume, M.; Komori, K.; Matsumoto, T.; Onohara, T.; Takeuchi, K.; Yonemitsu, Y.; Sugimachi, K., Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation, 2002, 105(10), 1226-1232.
13. Brown, D. A.; Kang, S. H.; Gryaznov, S. M.; DeDionisio, L.; Heidenreich, O.; Sullivan, S.; Xu, X.; Nerenberg, M. I., Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem., 1994, 269(43), 26801-5.
14. Burgess, T. L.; Fisher, E. F.; Ross, S. L.; Bready, J. V.; Qian, Y. X.; Bayewitch, L. A.; Cohen, A. M.; Herrera, C. J.; Hu, S. S.; Kramer, T. B.; et al., The antiproliferative activity of c-myb and cmyc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA, 1995, 92 (9), 4051-5.
15. Gao, W. Y.; Han, F. S.; Storm, C.; Egan, W.; Cheng, Y. C., Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol., 1992, 41(2), 223-229.
16. Hosoya, T.; Takeuchi, H.; Kanesaka, Y.; Yamakawa, H.; Miyano-Kurosaki, N.; Takai, K.; Yamamoto, N.; Takaku, H., Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett., 1999, 461(3), 136-140.
17. Gibson, I., Antisense approaches to the gene therapy of cancer-- 'Recnac'. Cancer Metastasis Rev., 1996, 15(3), 287-299.
18. Henry, S. P.; Bolte, H.; Auletta, C.; Kornbrust, D. J., Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology, 1997, 120(2), 145-155.
19. Henry, S. P.; Giclas, P. C.; Leeds, J.; Pangburn, M.; Auletta, C.; Levin, A. A.; Kornbrust, D. J., Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther., 1997, 281(2), 810-816.
20. Srinivasan, S. K.; Iversen, P., Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal., 1995, 9(2), 129-137.
21. Iversen, P. L.; Cornish, K. G.; Iversen, L. J.; Mata, J. E.; Bylund, D. B., Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)- adrenergic receptor antagonists. Toxicol. Appl. Pharmacol., 1999, 160(3), 289-296.
22. Crooke, S. T., Progress in antisense therapeutics. Hematol. Pathol., 1995, 9(2), 59-72.
23. Osako, M. K.; Tomita, N.; Nakagami, H.; Kunugiza, Y.; Yoshino, M.; Yuyama, K.; Tomita, T.; Yoshikawa, H.; Ogihara, T.; Morishita, R., Increase in nuclease resistance and incorporation of NF-kappaB decoy oligodeoxynucleotides by modification of the 3'- terminus. J. Gene. Med., 2007, 9(9), 812-819.
24. Vasir, J. K.; Labhasetwar, V., Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev., 2007, 59(8), 718-728.
25. Panyam, J.; Labhasetwar, V., Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55(3), 329-347.
26. Okada, H., One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev., 1997, 28(1), 43-70.
27. Kimura, S.; Egashira, K.; Chen, L.; Nakano, K.; Iwata, E.; Miyagawa, M.; Tsujimoto, H.; Hara, K.; Morishita, R.; Sueishi, K.; Tominaga, R.; Sunagawa, K., Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline- induced pulmonary arterial hypertension. Hypertension, 2009, 53(5), 877-883.
28. Tahara, K.; Samura, S.; Tsuji, K.; Yamamoto, H.; Tsukada, Y.; Bando, Y.; Tsujimoto, H.; Morishita, R.; Kawashima, Y., Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-coglycolide) nanospheres for inflammatory bowel disease. Biomaterials, 2011, 32(3), 870-878.
29. De Rosa, G.; Maiuri, M. C.; Ungaro, F.; De Stefano, D.; Quaglia, F.; La Rotonda, M. I.; Carnuccio, R., Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres. J. Gene. Med., 2005, 7(6), 771-781.
30. De Stefano, D.; De Rosa, G.; Maiuri, M. C.; Ungaro, F.; Quaglia, F.; Iuvone, T.; Cinelli, M. P.; La Rotonda, M. I.; Carnuccio, R., Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol. Res., 2009, 60(1), 33-40.